Current location:


Choose your location:


  • Varicella Vaccine, Live, was marketed

  • Quadrivalent Influenza Vaccine was marketed

  • 23-valent Pneumococcal Polysaccharide Vaccine was marketed

  • Initiated the "Anti-COVID-19 Action" program to R&D Inactivated COVID-19 vaccine, CoronaVac®, which was one of the first vaccines against COVID-19 in China to be approved for emergency use

  • SINOVAC's fourth vaccine industrial base in Daxing, Beijing was put into use

  • Sinovac (Singapore) Ltd. was founded